International Stem Cell CORP (ISCO): debt financing — International Stem Cell extends CEO loan of $2.5M to Sept 2026

International Stem Cell CORP

Extended maturity of $2.5M promissory note from CEO Andrey Semechkin from Sept 15, 2025 to Sept 15, 2026.
Original note was $2.7M issued Sept 2024; $200k repaid; outstanding principal $2.5M.
Accrued and unpaid interest of $799,064.44 carried forward, does not accrue additional interest.
Interest rate unchanged at 5.5% per annum; company may prepay without penalty.
Company's Co-Chairman and CEO is the noteholder; related-party transaction.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

International Stem Cell CORP amended loan of $2,500,000 with Dr. Andrey Semechkin at 5.5% per annum maturing September 15, 2026.

Instrument: loan
Principal: $2,500,000
Counterparty: Dr. Andrey Semechkin
Rate: 5.5% per annum
Maturity: September 15, 2026
Event: amendment

Exact text from the filing

On September 15, 2025, International Stem Cell Corporation (the “Company”) and Dr. Andrey Semechkin agreed to extend (until September 15, 2026) the maturity date of the loan (in the principal amount of $2,500,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated September 15, 2024 (the “Original Note”), and which would have been due on September 15, 2024.

View on SEC.gov

309 debt financings filed in the last 30 days. Browse all debt financings →

International Stem Cell CORP filing history →

Source: SEC EDGAR

accession 0001683168-25-007018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.